The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Curcumin: A new candidate for melanoma therapy?
Abstract
Melanoma remains among the most lethal cancers and, in spite of great attempts that have been made to increase the life span of patients with metastatic disease, durable and complete remissions are rare. Plants and plant extracts have long been used to treat a variety of human conditions; however, in many cases, effective doses of herbal remedies are associated with serious adverse effects. Curcumin is a natural polyphenol that shows a variety of pharmacological activities including anti‐cancer effects, and only minimal adverse effects have been reported for this phytochemical. The anti‐cancer effects of curcumin are the result of its anti‐angiogenic, pro‐apoptotic and immunomodulatory properties. At the molecular and cellular level, curcumin can blunt epithelial‐to‐mesenchymal transition and affect many targets that are involved in melanoma initiation and progression (e.g., BCl2, MAPKS, p21 and some microRNAs). However, curcumin has a low oral bioavailability that may limit its maximal benefits. The emergence of tailored formulations of curcumin and new delivery systems such as nanoparticles, liposomes, micelles and phospholipid complexes has led to the enhancement of curcumin bioavailability. Although in vitro and in vivo studies have demonstrated that curcumin and its analogues can be used as novel therapeutic agents in melanoma, curcumin has not yet been tested against melanoma in clinical practice. In this review, we summarized reported anti‐melanoma effects of curcumin as well as studies on new curcumin formulations and delivery systems that show increased bioavailability. Such tailored delivery systems could pave the way for enhancement of the anti‐melanoma effects of curcumin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543 · cited 1×
“Several studies have reported low or undetectable plasma/tissue levels of free curcumin.(46,47) However, it must be taken into account the metabolites and degradation products of curcumin, like curcumin sulfate, curcumin glucuronide and tetrahydrocurcumin possess significant and, in some cases, similar or stronger bio…”
BackgroundAggarwal, B. B., & Harikumar, K. B. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.06.010 · Cited by 1,716
Sharma, R. A., Gescher, A. J., & Steward, W. P. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.009 · Cited by 1,658
Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller, D., & Zhang, H.-G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.105 · Cited by 1,572
Dose escalation of a curcuminoid formulation
Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., Boggs, M. E., Crowell, J., Rock, C. L., & Brenner, D. E. (2006) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-6-10 · Cited by 1,394
Miller, A. J., & Mihm, M. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052166 · Cited by 1,339
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., Ng, C. S., Badmaev, V., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0024 · Cited by 1,331
Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature
Anand, P., Thomas, S. G., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Sung, B., Tharakan, S. T., Misra, K., Priyadarsini, I. K., Rajasekharan, K. N., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.008 · Cited by 1,205
Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.1.2 · Cited by 1,057
Cited by
Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies
Mirzaei, H., Shakeri, A., Rashidi, B., Jalili, A., Banikazemi, Z., & Sahebkar, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.098 · Cited by 517
Self-citationNLRP3 inflammasome: Its regulation and involvement in atherosclerosis
Hoseini, Z., Sepahvand, F., Rashidi, B., Sahebkar, A., Masoudifar, A., & Mirzaei, H. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25930 · Cited by 458
Self-citationImmune modulation by curcumin: The role of interleukin-10
Mollazadeh, H., Cicero, A. F. G., Blesso, C. N., Pirro, M., Majeed, M., & Sahebkar, A. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1358139 · Cited by 381
Self-citationMechanisms of apoptosis modulation by curcumin: Implications for cancer therapy
Mortezaee, K., Salehi, E., Mirtavoos‐mahyari, H., Motevaseli, E., Najafi, M., Farhood, B., Rosengren, R. J., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28122 · Cited by 340
Self-citationAbdollahi, E., Momtazi, A. A., Johnston, T. P., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25778 · Cited by 270
Self-citation
Metadata
- Authors
- Mirzaei, H., Naseri, G., Rezaee, R., Mohammadi, M., Banikazemi, Z., Mirzaei, H. R., Salehi, H., Peyvandi, M., Pawelek, J. M., & Sahebkar, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2016-07-04
- Volume
- 139
- Issue
- 8
- Pages
- 1683-1695
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2414660052
- Cited by
- 253
- References
- 144
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Curcumin: A new candidate for melanoma therapy? https://app.cochat.ai/papers/10.1002/ijc.30224
- The paper
- Mirzaei, H., Naseri, G., Rezaee, R., Mohammadi, M., Banikazemi, Z., Mirzaei, H. R., Salehi, H., Peyvandi, M., Pawelek, J. M., & Sahebkar, A. (2016). Curcumin: A new candidate for melanoma therapy? International Journal of Cancer. https://doi.org/10.1002/ijc.30224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.